The 2014 budget proposal for the Dept. of Health & Human Services contains some important boosts in the FDA’s coffers, including a $59 million increase the agency’s medical device review arm compared with 2012.
The new budget would provide the Dept. of Health & Human Services a total of $967.3 billion in outlays and $80.1 billion in discretionary spending, and it includes initiatives that aim to save $361.1 billion over a decade.
The budget sets aside $4.7 billion for FDA’s medical device, drug and biologic oversight, an increase of 21%, or $821 million, over 2012, according to the report.
Of that total, $2.6 billion is dedicated to medical product safety, including authority over medical devices, drugs and biologics.
Broken down further, the proposal allocates a total of $435 million for the FDA’s medical device program, $1.29 billion for human drugs and $338 million for biologics. Those budgets are meant to be supplemented by the FDA’s user fee programs through which the agency collects payment for reviewing new products.
The budget further recommends a $15 million "medical products reinspection" user fee that would put the full cost of a reinspection and associated follow-up squarely on a manufacturer should the review turn up health and safety violations.
The FDA fared better in the latest budget outline than some of its fellow agencies under HHS. The Centers for Disease Control & Prevention got a 1% boost over its 2012 levels, the National Institutes of Health got a 2% boost, and the Substance Abuse & Mental Health Services Admin. got a 0.1% boost.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.